Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
For Graves' disease patients undergoing radioactive iodine ablation, what is the preferred approach to steroid prophylaxis for Graves' orbitopathy?
Related Questions
For patients on desiccated bovine thyroid hormone therapy, how do you approach transitioning to synthetic thyroid hormone derivatives?
For patients with low risk, differentiated thyroid cancer, how do you navigate the decision between less aggressive treatments, such as lobectomy alone without radioactive iodine, and more aggressive strategies?
How do you assess and adjust treatment in patients who develops hypothyroidism after being on lithium for several years?
Do you recommend prescribing methimazole to prevent iodinated contrast media-induced exacerbation of thyrotoxicosis in patients with pre-existing hyperthyroidism?
Would you recommend RAI ablation therapy to patients with PTC who are s/p hemi-thyroidectomy and decline completion thyroidectomy despite meeting criteria based on pathology results?
Would you increase or maintain the same initial dose of methimazole for treatment of hyperthyroidism if symptoms and thyroid tests improve but are not normalized?
How often should TSH levels be monitored in patients with a history of Graves' disease who are in remission with negative TSI/TBII antibodies and off medical therapy?
Is a target TSH closer to the mid normal range justified in older individuals (age 70 or above) without any known cardiac ischemia or dysrhythmia or osteoporosis?
What is your approach to treating subacute thyroiditis in a patient presenting with recurrent fevers?
How does papillary thyroid carcinoma with tall cell features (PTC TCF) compare to tall cell variant papillary thyroid carcinoma (TCV PTC) with regards to their clinicohistopathological features and risk of recurrence?
